Circulating Tumor Cells, From Biotech Innovation to Clinical Utility Part A

1st Edition, Volume 381 - September 19, 2023
Editors: Carolina Reduzzi, Lorenzo Gerratana, Massimo Cristofanilli
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 6 1 3 4 - 6
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 6 1 3 5 - 3

"Circulating Tumor Cells, from biotech innovation to clinical utility" provides an overview of the most recent technological and clinical advances with regards to the study of ci… Read more

Circulating Tumor Cells, From Biotech Innovation to Clinical Utility Part A

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

"Circulating Tumor Cells, from biotech innovation to clinical utility" provides an overview of the most recent technological and clinical advances with regards to the study of circulating tumor cells (CTCs) in solid tumors. The volumes cover studies on CTCs in breast, prostate, colorectal and lung cancer, with a focus on clinical utility, and also include methodological and biological topics such as CTC culture, multi-omic characterization of CTCs, atypical CTC populations and interaction between CTCs and immunity.

Cover image
Title page
Table of Contents
Series Page
Copyright
Contributors
Circulating tumor cells: from biotech innovation to clinical utility
Conflicts of interest
References
Chapter One: Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancer
Abstract
1 Introduction
2 Clinical studies on CTCs in early breast cancer
3 Prognostic value of CTCs in early breast cancer
4 Predictive value of CTCs in early breast cancer
5 Other CTCs related early breast cancer studies
6 Clinical studies on CTCs in metastatic breast cancer
7 Prognostic value of CTCs in metastatic breast cancer
8 Predictive value of CTCs in metastatic breast cancer
9 Conclusions
References
Chapter Two: Can we define breast cancer HER2 status by liquid biopsy
Highlights
Abstract
1 Introduction
2 Assessment of HER2 Status in ctDNA
3 Use of ctDNA as a readout of ERBB2 amplification
4 HER2 status in CTCs: Historical results, biological insights and clinical relevance
5 Initial studies
6 Introduction of automated image-analysis tools
7 Assessment of ERBB2 amplification in CTCs
8 Significance of HER2 status in CTCs
9 Challenges in CTC HER2 status assessment
10 Reappraisal of HER2 status as a spectrum
11 Challenges in HER2-low diagnostics
12 Evaluation of HER2 status of CTCs by WGS
13 Conclusions
References
Chapter Three: Models to study CTCs and CTC culture methods
Abstract
1 Introduction
2 Animal models for the study of CTCs
3 CTC culture/expansion methods
4 Conclusions
References
Chapter Four: Settling the uncertainty about unconventional circulating tumor cells: Epithelial-to-mesenchymal transition, cell fusion and trogocytosis
Abstract
1 Introduction
2 Epithelial and mesenchymal transition (EMT)
3 Cell to cell fusion
4 Trogocytosis
5 Conclusions
Footnotes
References
Chapter Five: Circulating tumor cells in cancer-risk populations as a cancer interception tool
Abstract
1 Liquid biopsy
2 Circulating tumor cells isolation and characterization
3 Circulating tumor cells and cancer interception. Premalignant lesions
4 Cancer interception vs metastasis interception
5 In summary
Acknowledgments
References
Chapter Six: Circulating tumor cells and host immunity: A tricky liaison
Abstract
1 The immunoediting process from the tumor site to the periphery
2 Circulating immune cells: Heroes and villains in the fight against CTCs
3 How do CTCs fool the immune system
4 Prognostic role of tumor and host integrated analyses
5 Conclusion
References

Carolina Reduzzi

Carolina Reduzzi is a Research Associate at Weill Cornell Medicine. She obtained a degree with laude in Biology Applied to Biomedical Research in 2014 at the University of Milan. She has been working on liquid biopsy for the last decade, first at the National Cancer Institute of Milan (Fondazione IRCCS Istituto Nazionale dei Tumori), where she obtained her PhD in 2020, and subsequently at the Northwestern University of Chicago, where she conducted her postdoctoral research on circulating tumor cells in breast cancer. Since 2022 she is the Director of Dr. Cristofanilli’s laboratory at Weill Cornell Medicine. She is a member of the Young Committee of the International Society of Liquid Biopsy, reviewer for different journals including Cell Reports, Scientific Reports, Cancers and BMC Cancer, and grant reviewer for the Italian Health Ministry and the Fondation Toulouse Cancer Santé.

Affiliations and expertise

Department of Medicine, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10021

Lorenzo Gerratana

Lorenzo Gerratana is a Physician scientist at the IRCCS CRO Aviano National cancer Institute and a Research fellow at the Department of Medicine at the University of Udine. After graduating as MD, he focused on DNA repair in vitro models in Triple Negative Breast Cancer, clinical methodology and endpoint analysis. As a medical oncology fellow at the University of Udine and visiting scholar at the Northwestern University of Chicago he focused his research on liquid biopsy and big data, with the aim of transferring promising tissue and liquid biopsy-based biomarkers and treatment strategies from the bench to the bedside, with a pragmatic imprinting towards clinical utility and transferability. He currently serves as Attending Physician at the IRCCS CRO Aviano National Cancer Institute as part of the Breast Unit and the Precision Medicine Multidisciplinary Team.

Affiliations and expertise

Department of Medicine (DAME) - University of Udine, Aviano, ITALY

Massimo Cristofanilli

Massimo Cristofanilli, MD, is an accomplished board-certified medical oncologist with more than two decades of experience as physician, investigator, researcher and leader. He has demonstrated original and innovative vision in the field of molecular diagnostics, liquid biopsy, translational research and drug development. Additionally, Dr. Cristofanilli has an extensive background in clinical trial design and is a key thought leader in the field of metastatic and locally advanced breast cancer. At Weill Cornell Medicine and NewYork-Presbyterian, Dr. Cristofanilli serves as the Director of Breast Medical Oncology, the Associate Director of Precision Oncology at the Meyer Cancer Center (MCC), and the co-leader of the MCC Breast Cancer Disease Management Team, as well as the Scientific Director of the Englander Institute of Precision Medicine (EIPM). Dr. Cristofanilli received his medical degree from the University “La Sapienza” in Rome with Honors where he subsequently completed his fellowship in medical oncology. He completed an Internal Medicine residency at Cabrini Medical Center in New York and a medical oncology fellowship at The University of Texas MD Anderson Cancer Center, where he also served as Faculty in the Department of Breast Medical Oncology for more than a decade.Dr. Cristofanilli has held several leadership positions over the years, including Chairman of Medical Oncology and Associate Director of Clinical Research at the Fox Chase Cancer Center and Associate Director of Translational Research at Thomas Jefferson University. From 2015-2021, Dr. Cristofanilli was Professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago where he also served as the Director of the Breast Disease Team, Director of the Robert Lurie Cancer Center OncoSET Precision Medicine Program, and Associate Director of Clinical Research. In addition to his clinical expertise, Dr. Cristofanilli’s research focuses on biomarkers of endocrine resistance in breast cancer, liquid biopsies and novel drug development. His research in the areas of novel drug development, circulating tumor cells (CTCs) and ctDNA have led to improved treatments for breast cancer. Dr. Cristofanilli is an internationally recognized expert in the research and treatment of Inflammatory Breast Cancer (IBC), the most aggressive and deadly form of breast cancer. He is the founder and President of the IBC International Consortium (IBC-IC). Additionally, Dr. Cristofanilli is globally recognized for his contributions on the detection of micrometastatic disease in breast cancer and a key opinion leader in drug development in hormone-receptor positive metastatic breast cancer. He has co-authored more than 400 peer-reviewed manuscripts.

Affiliations and expertise

Department of Medicine, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10021